Gilead Sciences Stock: Rebound of 3.73% at Close After a Declining Week
Gilead Sciences stock closed on Tuesday, November 11 at $122.56, marking a 3.73% gain for the day. This movement comes four days after the disappointing announcement regarding the clinical trials of its Trodelvy treatment. Overall for the week, the stock is still slightly down by 0.36%, remaining far from the highs reached earlier in the year.
A Stabilizing Attempt After a Volatile Week
Tuesday's rebound represents an attempt to stabilize after a week marked by volatility. At $122.56, the stock is approaching its pre-fall levels, although it has not yet fully erased the losses from Thursday, November 7. Trading volume was recorded at 6,059,485 shares, representing 0.49% of the capitalization, indicating moderate activity without a particular rush from investors. This closure occurs in a mixed American market context, with the S&P 500 showing a gain of 0.36% on the same day. Since the beginning of the year, Gilead Sciences has nevertheless recorded a positive performance of 26.31%, outperforming the broader American index which has gained 18.33% over the same period. The annual outlook remains favorable, despite recent turbulence.
Context of a Challenging Week Partially Explains Movements
The context of a difficult week partly explains the observed movements. On Thursday, November 7, Gilead announced that its drug Trodelvy had not achieved its primary objective in an advanced phase trial involving patients with hormone receptor-positive, HER2-negative advanced breast cancer. The trial aimed to demonstrate an improvement in progression-free survival compared to conventional chemotherapy. This clinical disappointment triggered a drop of 3.70% on the same day, bringing the stock to $120.36 in early trading. Tuesday's rebound represents a partial recovery of these losses, suggesting some market resilience to this setback. It is noteworthy that Trodelvy remains approved for patients with advanced breast cancer who have already received other treatments, potentially limiting the impact of this failure to only the prospects of expanding therapeutic indications. The week's net decline of 0.36% reflects the balance between this bad news and attempts to rebound at the end of the period.
